Copenhagen: A patient who falls ill on holiday in another member state still, in 2026, often depends on memory and translation to explain their own medical history. The European Health Data Space, the regulation that came into force in March last year, is meant to consign that fragility to the past. This year the framework moves from statute to scaffolding, and the institutions that will run it are taking shape.
The regulation builds two storeys. The first, primary use, gives citizens stronger control over their own electronic health records and the right to have them follow them across borders, so that patient summaries, prescriptions and images can be read by a clinician anywhere in the Union. The second, secondary use, opens anonymised or pseudonymised health data to researchers, regulators and public health bodies under strict conditions, a resource its advocates believe could accelerate everything from cancer studies to pandemic preparedness.
2026 is a year of plumbing rather than headlines. The first implementing act establishing the EHDS Board, the body that will steer the system, was adopted in April, giving the project a governance spine. By the start of the year, providers of electronic health record systems were expected to begin certifying their products for interoperability and security, the unglamorous technical compliance on which the whole edifice rests. Guidelines on the secondary use of data have been moving through consultation, sketching the rules that will decide who may query Europe’s collective medical memory and on what terms.
The full machinery arrives in stages. Key parts of the regulation apply from March 2027, with the cross-border exchange of patient summaries, ePrescriptions and eDispensations expected to function across all member states by March 2029, and further milestones stretching to the next decade. The deliberate pace reflects the scale of the undertaking and the uneven starting points of national systems.
That unevenness is the central worry. Some countries, particularly in the Nordics and the Baltics, already run mature digital health infrastructures and will adapt with relative ease. Others are starting closer to paper, and the gap raises the prospect of a two-speed health data union in which the benefits flow first to citizens who least needed them. Critics also press the privacy question: pooling the most intimate category of personal data, even behind safeguards, demands public trust that can be lost far faster than it is built, and a single high-profile breach could set the project back years.
For the medical technology and life sciences industries the stakes are commercial as well as clinical. A genuine single market for health data would be one of the largest research resources in the world, and companies are already weighing how to position themselves around it.
The coming months will test whether Europe can build the trust as diligently as it builds the technical standards. The certification deadlines and the new Board are quiet milestones, but they are the ones on which the grander promise of seamless, borderless care ultimately depends.




